MiniMed: Next-Generation Diabetes Platform Supports A Buy Rating

Impact · against what's priced in

MiniMed Group (MMED) shows strong top-line momentum and favorable product timing, though these gains are partially offset by deteriorating margins and net losses. The overall outlook remains positive due to high liquidity and international expansion.

MMED+0.40

No priced-in read yet

In context

Double-digit revenue growth and product launches ahead of schedule are strong catalysts, though they are tempered by gross margin compression and widened net losses in FY 2026.

Read from the article alone

• revenue growth▲7%
• MMED
• cgms
• diabetes
• ipo
• medtech
• price target
• spin off

Top 1 mover · tap to explore